Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

LPTX – Leap Therapeutics Inc

Leap Therapeutics, Inc.
LPTX
$0.2872
Name : Leap Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $11,901,425.00
EPSttm : -1.67
finviz dynamic chart for LPTX
Leap Therapeutics, Inc.
$0.2872
9.70%
$0.0256

Float Short %

5.19

Margin Of Safety %

Put/Call OI Ratio

0.14

EPS Next Q Diff

0.13

EPS Last/This Y

0.7

EPS This/Next Y

0.58

Price

0.28

Target Price

5.5

Analyst Recom

3

Performance Q

-28.29

Relative Volume

0.72

Beta

-0.27

Ticker: LPTX




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02LPTX0.35860.10999.993991
2025-06-03LPTX0.3710.100.003996
2025-06-04LPTX0.40490.100.004039
2025-06-05LPTX0.38910.100.004122
2025-06-06LPTX0.3850.100.164137
2025-06-09LPTX0.41510.100.014208
2025-06-10LPTX0.420.100.004311
2025-06-11LPTX0.4410.100.174322
2025-06-12LPTX0.41240.100.004335
2025-06-13LPTX0.41380.100.004335
2025-06-16LPTX0.4010.100.004336
2025-06-17LPTX0.38820.100.004360
2025-06-18LPTX0.40970.100.004375
2025-06-20LPTX0.380.090.694459
2025-06-23LPTX0.31610.120.003182
2025-06-24LPTX0.27910.120.703272
2025-06-25LPTX0.28380.140.063517
2025-06-26LPTX0.27260.140.243548
2025-06-27LPTX0.26160.140.003580
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02LPTX0.3644.2- -1.11
2025-06-03LPTX0.3744.2- -1.11
2025-06-04LPTX0.4144.2- -1.11
2025-06-05LPTX0.4044.2- -1.11
2025-06-06LPTX0.3944.2- -1.11
2025-06-09LPTX0.4144.2- -1.11
2025-06-10LPTX0.4244.2- -1.11
2025-06-11LPTX0.4444.2- -1.11
2025-06-12LPTX0.4244.2- -1.11
2025-06-13LPTX0.4144.2- -1.11
2025-06-16LPTX0.4044.2- -1.11
2025-06-17LPTX0.3844.2- -1.11
2025-06-18LPTX0.3944.2- -1.11
2025-06-20LPTX0.3844.2- -1.11
2025-06-23LPTX0.3244.2- -1.11
2025-06-24LPTX0.2844.2- -1.11
2025-06-25LPTX0.2844.2- -1.11
2025-06-26LPTX0.2744.2- -1.11
2025-06-27LPTX0.2844.2- -1.11
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02LPTX0.00-21.276.15
2025-06-03LPTX0.00-21.276.15
2025-06-04LPTX0.00-21.276.15
2025-06-05LPTX0.00-21.276.15
2025-06-06LPTX0.00-21.276.15
2025-06-09LPTX0.00-21.276.15
2025-06-11LPTX0.00-21.275.01
2025-06-12LPTX0.00-21.275.01
2025-06-13LPTX0.00-21.275.01
2025-06-16LPTX0.00-21.415.01
2025-06-17LPTX0.00-21.415.01
2025-06-18LPTX0.00-21.415.01
2025-06-19LPTX0.00-21.415.01
2025-06-20LPTX0.00-21.415.01
2025-06-24LPTX0.00-21.415.01
2025-06-25LPTX0.00-21.415.01
2025-06-26LPTX0.00-21.415.19
2025-06-27LPTX0.00-21.415.19
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.37

Avg. EPS Est. Current Quarter

-0.29

Avg. EPS Est. Next Quarter

-0.24

Insider Transactions

Institutional Transactions

-21.41

Beta

-0.27

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

5

Growth Score

21

Sentiment Score

16

Actual DrawDown %

99.3

Max Drawdown 5-Year %

-99.3

Target Price

5.5

P/E

Forward P/E

PEG

P/S

P/B

0.52

P/Free Cash Flow

EPS

-1.7

Average EPS Est. Cur. Y​

-1.11

EPS Next Y. (Est.)

-0.53

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.72

Return on Equity vs Sector %

-356.9

Return on Equity vs Industry %

-339.1

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.15

EBIT Estimation

Leap Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 24
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
stock quote shares LPTX – Leap Therapeutics Inc Stock Price stock today
news today LPTX – Leap Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch LPTX – Leap Therapeutics Inc yahoo finance google finance
stock history LPTX – Leap Therapeutics Inc invest stock market
stock prices LPTX premarket after hours
ticker LPTX fair value insiders trading